Researchers from the Institut de Recerca Sant Pau and CIBERCV identified the LRP5 protein as a component of platelet activation. This study was published in the journal European Heart Journal, which also included an independent editorial on new antithrombotic strategies.

The LRP5 protein influences platelet aggregation and arterial thrombus formation as part of the WNT signaling pathway. The research team utilized murine models lacking the LRP5 protein and conducted experiments using human blood and platelets. In experimental arterial thrombosis models, control animals experienced complete carotid artery occlusion in approximately 21 minutes, while LRP5-deficient mice maintained vessel patency for a 30-minute observation period.

Maria Borrell-Pages, a researcher and corresponding author, said, "We have observed that both the genetic deletion of LRP5 and its pharmacological inhibition very significantly reduce platelet activation and thrombus formation in preclinical models, but with a much lower bleeding impact than that of classic antiplatelet agents such as aspirin or clopidogrel." Pharmacological inhibition of LRP5 in human blood samples decreased platelet aggregation and thrombus formation under high-flow conditions.

LRP5 interacts directly with the platelet P2Y12 receptor, which is a therapeutic target for certain antiplatelet medications. Experimental data indicate that LRP5 regulates P2Y12 receptor function during platelet activation. Blocking LRP5 or its absence reduces the P2Y12 receptor's capacity to transmit signals for platelet activation and aggregation. Borrell-Pages stated, "What we see is that LRP5 participates in central mechanisms of platelet activation and communication. Inhibiting this protein alters key processes needed to stabilize and amplify thrombus formation."

Research regarding LRP5 as a potential therapeutic target remains in the preclinical stage. LRP5 is also involved in cardiovascular, neuronal, and bone metabolism processes. This suggests that future therapeutic applications would need to specifically target platelets.

No independent assessment was available for this report.